Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) - guidance (TA582)

NICE Accredited

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
24 May 2019

Abstract

NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults because Ipsen Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance